A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1500 participants.

Also called NCT07784270

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,500 participants (planned count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07784270
  • EudraCT 2025-524616-11
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Canada, Chile, China, Germany, Hungary, India, Japan, Poland, Slovakia, South Korea, Spain, Taiwan, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07784270. Randomized; quadruple masking; primary purpose treatment. Start 2026-08-20 (actual); primary completion 2028-08-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
Acronym
SELENE 2
Condition
Obesity or Overweight
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Lenbelintide
Intervention (Drug)
Placebo
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct07784270
Content hash
0417af705ba83a1510ca7f5d644813851cc3d23437df0cea6fa3400d991389d1